Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Fischer A, Zimovetz E, Ling C, Esser D, Shoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017 Nov;16(11):1147-54. doi: 10.1016/j.autrev.2017.09.010
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.
Melendez J, Galli I, Boric K, Ortega A, Zuniga L, Henriquez-Roldan CF, Cardenas AM. Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement. Psychopharmacology (Berl). 2005 Aug;181(1):21-6. doi: 10.1007/s00213-005-2228-0
Castellsague J, García-Rodríguez LA, Duque A, Perez-Gutthann S. Risk of severe cutaneous disorders in users of oral antifungals. BMC Dermatology. 2002 Nov 28;2(14). doi: 10.1186/1471-5945-2-14
Dykstra LA, Granger AL, Allen RM, Zhang X, Rice KC. Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure. Psychopharmacology (Berl). 2002 Oct 1;163(3-4):420-9.
Castellsague J, Garcia-Rodriuez LA, Duque A, Perez S. Risk of serious skin disorders among users of oral antifungals: a population-based study. BMC Dermatology. 2002;2:14.